Pipeline development milestones

A phase III study for PTS to treat NSCLC-MAO has been completed in China (2012). In the clinical trial, 8 patients with ACC were treated with PTS and the efficacy was significant. ACC is a rare disease (incidence rate of 1/ 10,000), and PTS has been granted an orphan drug designation by FDA to treat ACC in 2017. We have also completed a consultation with FDA in 2019 for initiating a phase II/III study to treat inoperable ACC-MAO patients with PTS.